ETF Home ETF List Shorted Stocks Home About

Portfolio Holdings Detail for ISIN IE00BD1F4N50
Stock Name / FundiShares Edge MSCI USA Momentum Factor UCITS ETF USD (Acc) GBP
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerIUMF(GBX) LSE
ETF TickerIUMO(USD) LSE
ETF TickerQDVA(EUR) F
ETF TickerIUMF.LS(GBX) CXE
ETF TickerIUMO.LS(USD) CXE
ETF TickerQDVA.DE(EUR) CXE
ETF TickerIUMF.L(GBP) LSE
ETF TickerIUMO.L(GBP) LSE

Holdings detail for ALNY

Stock NameAlnylam Pharmaceuticals Inc
TickerALNY(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS02043Q1076
LEI529900S3ZI14OWRJII50

Show aggregate ALNY holdings

News associated with ALNY

Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $500.00
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price increased by Royal Bank Of Canada from $435.00 to $500.00 in a report issued on Friday morning,Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock. ALNY has been the topic of several other reports. The Goldman Sachs Group boosted their price […] - 2025-09-22 02:32:43
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $520.00 Price Target at Bank of America
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective raised by Bank of America from $453.00 to $520.00 in a research report report published on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. A number of other equities analysts have also weighed in on ALNY. Oppenheimer upgraded shares […] - 2025-09-18 04:26:54
The Goldman Sachs Group Forecasts Strong Price Appreciation for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price increased by The Goldman Sachs Group from $504.00 to $566.00 in a report published on Tuesday,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the biopharmaceutical company’s stock. Several other equities research analysts have also commented on the stock. Chardan Capital lifted […] - 2025-09-17 03:14:44
Brokerages Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) PT at $421.28
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twenty-seven analysts that are covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and twenty-three have issued a buy recommendation on the company. The average 1 year target price […] - 2025-09-15 02:47:58
Alnylam Announces Pricing Of Upsized Offering Of $575 Mln Convertible Senior Notes Due 2028
(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) announced the pricing of its private offering of $575 million aggregate principal amount of 0.00% convertible senior notes due 2028. The size of the offering was increased from the previously announced offering of $500 million aggre - 2025-09-10 00:33:28
Alnylam Pharma Commences Private Offering Of $500 Mln Of Convertible Senior Notes Due 2028
(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) announced that it has commenced a private offering of $500 million aggregate principal amount of convertible senior notes due 2028. In connection with this offering, Alnylam expects to grant the initial purchasers of the notes an op - 2025-09-09 00:30:30
ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win
Alnylam and Roche report positive phase II KARDIA-3 results for zilebesiran in high-risk hypertension patients, fueling momentum for a phase III study. - 2025-09-01 11:50:00
Notable ETF Outflow Detected - XBI, ALNY, HALO, INSM
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $119.6 million dollar outflow -- that's a 2.2% decrease week over week - 2025-08-28 11:56:11
Dennis A. Ausiello Sells 31,448 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) Director Dennis A. Ausiello sold 31,448 shares of the company’s stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $436.58, for a total value of $13,729,567.84. Following the completion of the sale, the director directly owned 911 shares in […] - 2025-08-18 05:14:55
LPL Financial LLC Buys 2,107 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
LPL Financial LLC grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 11.3% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 20,679 shares of the biopharmaceutical company’s stock after acquiring an additional 2,107 shares during the period. LPL Financial LLC’s holdings […] - 2025-08-13 05:04:56
XBI, ALNY, INSM, INCY: Large Outflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $202.3 million dollar outflow -- that's a 4.3% decrease week over week - 2025-08-12 11:55:54
Cetera Investment Advisers Has $2.17 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Cetera Investment Advisers raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 68.1% during the first quarter, Holdings Channel reports. The firm owned 8,017 shares of the biopharmaceutical company’s stock after purchasing an additional 3,247 shares during the period. Cetera Investment Advisers’ holdings in Alnylam Pharmaceuticals were worth $2,165,000 at the end […] - 2025-08-08 04:44:59
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded at Oppenheimer
Oppenheimer upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) from a market perform rating to an outperform rating in a research report sent to investors on Monday, Marketbeat.com reports. The brokerage currently has $490.00 target price on the biopharmaceutical company’s stock. ALNY has been the subject of several other reports. Barclays lifted their price […] - 2025-08-07 02:54:47
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded by Wolfe Research to Peer Perform Rating
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) was upgraded by equities research analysts at Wolfe Research from an “underperform” rating to a “peer perform” rating in a research report issued on Monday, Marketbeat reports. A number of other brokerages have also recently issued reports on ALNY. Canaccord Genuity Group lifted their price target on shares […] - 2025-08-06 03:02:54
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $400.00 at Chardan Capital
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective lifted by Chardan Capital from $325.00 to $400.00 in a research report report published on Friday,Benzinga reports. Chardan Capital currently has a buy rating on the biopharmaceutical company’s stock. Several other research analysts have also issued reports on ALNY. Needham & Company LLC raised their […] - 2025-08-04 02:48:47
Needham & Company LLC Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $478.00
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target hoisted by Needham & Company LLC from $377.00 to $478.00 in a research report report published on Thursday morning,Benzinga reports. Needham & Company LLC currently has a buy rating on the biopharmaceutical company’s stock. A number of other research analysts also recently commented on the […] - 2025-08-03 05:28:56
Noteworthy ETF Outflows: XBI, MRNA, ALNY, EXEL
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $225.3 million dollar outflow -- that's a 4.6% decrease week over week - 2025-07-30 11:49:03
Y Intercept Hong Kong Ltd Has $1 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Y Intercept Hong Kong Ltd lessened its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 17.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,720 shares of the biopharmaceutical company’s stock after selling 796 shares during the period. […] - 2025-07-25 06:12:53
Victory Capital Management Inc. Cuts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Victory Capital Management Inc. lowered its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 5.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,649 shares of the biopharmaceutical company’s stock after selling 2,148 shares during the period. Victory Capital […] - 2025-07-25 05:14:50
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of “Moderate Buy” from Brokerages
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the twenty-six research firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and twenty-two have assigned a buy recommendation to the […] - 2025-07-24 06:26:55
Alnylam Pharmaceuticals (NASDAQ:ALNY) Now Covered by Truist Financial
Truist Financial initiated coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research report sent to investors on Monday, Marketbeat reports. The firm issued a buy rating and a $385.00 price target on the biopharmaceutical company’s stock. A number of other equities research analysts also recently issued reports on ALNY. Jefferies Financial […] - 2025-07-22 03:14:59
Nisa Investment Advisors LLC Cuts Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Nisa Investment Advisors LLC cut its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 38.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,155 shares of the biopharmaceutical company’s stock after selling 5,162 shares during […] - 2025-07-14 05:54:56
Crossmark Global Holdings Inc. Takes Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Crossmark Global Holdings Inc. purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 1,018 shares of the biopharmaceutical company’s stock, valued at approximately $275,000. Other hedge funds have also modified their holdings of the […] - 2025-07-14 05:14:48
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Vontobel Holding Ltd.
Vontobel Holding Ltd. decreased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 6.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,691 shares of the biopharmaceutical company’s stock after selling 113 shares during the […] - 2025-07-08 04:40:51
Mirae Asset Global Investments Co. Ltd. Sells 2,596 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Mirae Asset Global Investments Co. Ltd. reduced its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 28.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,534 shares of the biopharmaceutical company’s stock after selling 2,596 shares during the […] - 2025-07-04 04:52:27
Wells Fargo & Company Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $333.00
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its price target lifted by research analysts at Wells Fargo & Company from $287.00 to $333.00 in a report released on Monday,Benzinga reports. The brokerage presently has an “equal weight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price objective would suggest a potential upside […] - 2025-07-02 03:05:01
Diversified Trust Co Sells 999 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Diversified Trust Co cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 40.3% in the first quarter, Holdings Channel reports. The institutional investor owned 1,482 shares of the biopharmaceutical company’s stock after selling 999 shares during the period. Diversified Trust Co’s holdings in Alnylam Pharmaceuticals were worth $400,000 as of […] - 2025-07-01 07:10:56
Sequoia Financial Advisors LLC Boosts Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Sequoia Financial Advisors LLC lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 3.0% in the first quarter, HoldingsChannel reports. The fund owned 3,395 shares of the biopharmaceutical company’s stock after acquiring an additional 99 shares during the period. Sequoia Financial Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $917,000 […] - 2025-07-01 05:22:50
Alnylam Pharmaceuticals (NASDAQ:ALNY) Sets New 12-Month High Following Analyst Upgrade
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) hit a new 52-week high on Monday after Wells Fargo & Company raised their price target on the stock from $287.00 to $333.00. Wells Fargo & Company currently has an equal weight rating on the stock. Alnylam Pharmaceuticals traded as high as $327.05 and last […] - 2025-07-01 02:27:01
Kentucky Retirement Systems Buys New Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Kentucky Retirement Systems bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 8,794 shares of the biopharmaceutical company’s stock, valued at approximately $2,375,000. Several other institutional investors and […] - 2025-06-24 06:20:52

iShares Edge MSCI USA Momentum Factor UCITS ETF USD (Acc) GBP ALNY holdings

DateNumber of ALNY Shares HeldBase Market Value of ALNY SharesLocal Market Value of ALNY SharesChange in ALNY Shares HeldChange in ALNY Base ValueCurrent Price per ALNY Share HeldPrevious Price per ALNY Share Held
2025-12-18 (Thursday)7,700USD 3,049,508ALNY holding increased by 37499USD 3,049,5080USD 37,499 USD 396.04 USD 391.17
2025-12-16 (Tuesday)7,700USD 3,012,009ALNY holding decreased by -2541USD 3,012,0090USD -2,541 USD 391.17 USD 391.5
2025-12-15 (Monday)7,700USD 3,014,550ALNY holding decreased by -46585USD 3,014,5500USD -46,585 USD 391.5 USD 397.55
2025-12-12 (Friday)7,700USD 3,061,135ALNY holding decreased by -116116USD 3,061,1350USD -116,116 USD 397.55 USD 412.63
2025-12-11 (Thursday)7,700ALNY holding decreased by -97USD 3,177,251ALNY holding increased by 23676USD 3,177,251-97USD 23,676 USD 412.63 USD 404.46
2025-12-10 (Wednesday)7,797USD 3,153,575ALNY holding decreased by -83817USD 3,153,5750USD -83,817 USD 404.46 USD 415.21
2025-12-09 (Tuesday)7,797ALNY holding increased by 485USD 3,237,392ALNY holding increased by 93086USD 3,237,392485USD 93,086 USD 415.21 USD 430.02
2025-12-08 (Monday)7,312ALNY holding decreased by -388USD 3,144,306ALNY holding decreased by -383218USD 3,144,306-388USD -383,218 USD 430.02 USD 458.12
2025-12-05 (Friday)7,700USD 3,527,524ALNY holding decreased by -55594USD 3,527,5240USD -55,594 USD 458.12 USD 465.34
2025-12-04 (Thursday)7,700USD 3,583,118ALNY holding decreased by -61215USD 3,583,1180USD -61,215 USD 465.34 USD 473.29
2025-12-03 (Wednesday)7,700USD 3,644,333ALNY holding increased by 64372USD 3,644,3330USD 64,372 USD 473.29 USD 464.93
2025-12-02 (Tuesday)7,700USD 3,579,961ALNY holding increased by 79849USD 3,579,9610USD 79,849 USD 464.93 USD 454.56
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ALNY by Blackrock for IE00BD1F4N50

Show aggregate share trades of ALNY

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-12-11SELL-97414.220402.220 403.420USD -39,132 328.10 Loss of -7,306 on sale
2025-12-09BUY485433.305414.450 416.336USD 201,923 327.40
2025-12-08SELL-388449.780423.450 426.083USD -165,320 326.96 Loss of -38,461 on sale
2025-12-01SELL-9462.930448.265 449.732USD -4,048 323.94 Loss of -1,132 on sale
2025-11-25SELL-123441.820428.570 429.895USD -52,877 321.80 Loss of -13,296 on sale
2025-11-24BUY1,147444.670420.345 422.778USD 484,926 321.29
2025-11-18SELL-89469.110456.270 457.554USD -40,722 318.89 Loss of -12,341 on sale
2025-11-10SELL-172449.680440.930 441.805USD -75,990 315.12 Loss of -21,790 on sale
2025-11-06SELL-86445.490429.000 430.649USD -37,036 313.91 Loss of -10,040 on sale
2025-11-03BUY172457.260429.615 432.379USD 74,369 312.21
2025-10-24SELL-86463.430469.290 468.704USD -40,309 307.55 Loss of -13,860 on sale
2025-10-23BUY172464.000468.860 468.374USD 80,560 306.76
2025-10-22BUY86464.900480.530 478.967USD 41,191 305.96
2025-10-21SELL-85474.000490.050 488.445USD -41,518 305.11 Loss of -15,584 on sale
2025-10-20BUY85491.220495.550 495.117USD 42,085 304.16
2025-10-14SELL-86469.360479.690 478.657USD -41,165 300.59 Loss of -15,314 on sale
2025-10-01BUY255460.650467.420 466.743USD 119,019 296.38
2025-09-30BUY85456.000459.300 458.970USD 39,012 295.52
2025-09-15SELL-85461.140466.240 465.730USD -39,587 288.42 Loss of -15,071 on sale
2025-09-11SELL-85468.580474.340 473.764USD -40,270 287.40 Loss of -15,841 on sale
2025-09-08SELL-170455.030463.000 462.203USD -78,575 284.28 Loss of -30,248 on sale
2025-08-19BUY315458.280462.880 462.420USD 145,662 279.13
2025-08-04SELL-189419.560422.640 422.332USD -79,821 276.55 Loss of -27,553 on sale
2025-07-31BUY64392.240402.430 401.411USD 25,690 275.08
2025-07-30SELL-64339.800345.980 345.362USD -22,103 274.68 Loss of -4,524 on sale
2025-07-25SELL-64328.810331.500 331.231USD -21,199 273.68 Loss of -3,683 on sale
2025-07-24BUY128328.000332.190 331.771USD 42,467 273.34
2025-07-21BUY192320.520328.700 327.882USD 62,953 272.37
2025-07-18BUY192320.530325.620 325.111USD 62,421 272.06
2025-07-10BUY384322.640324.820 324.602USD 124,647 270.78
2025-07-07SELL-252324.130328.240 327.829USD -82,613 269.77 Loss of -14,632 on sale
2025-07-03SELL-63331.910333.700 333.521USD -21,012 268.91 Loss of -4,070 on sale
2025-06-30SELL-252326.090327.210 327.098USD -82,429 268.09 Loss of -14,869 on sale
2025-06-27BUY504322.830323.200 323.163USD 162,874 267.71
2025-06-24SELL-189325.000326.030 325.927USD -61,600 266.55 Loss of -11,221 on sale
2025-06-23SELL-63313.130314.780 314.615USD -19,821 266.22 Loss of -3,049 on sale
2025-06-20SELL-189309.700314.500 314.020USD -59,350 265.90 Loss of -9,094 on sale
2025-06-18SELL-248312.320317.540 317.018USD -78,620 265.22 Loss of -12,846 on sale
2025-06-17BUY372308.710309.060 309.025USD 114,957 264.90
2025-06-13BUY124307.990308.020 308.017USD 38,194 264.25
2025-06-12SELL-620304.670307.480 307.199USD -190,463 263.94 Loss of -26,821 on sale
2025-06-11BUY124298.580303.850 303.323USD 37,612 263.67
2025-06-05SELL-62308.000308.530 308.477USD -19,126 262.41 Loss of -2,856 on sale
2025-06-04BUY62305.310308.930 308.568USD 19,131 262.07
2025-05-30SELL-1,740304.560306.000 305.856USD -532,189 261.03 Loss of -78,002 on sale
2025-05-29SELL-88292.900293.220 293.188USD -25,801 260.77 Loss of -2,853 on sale
2025-05-23SELL-176289.960291.220 291.094USD -51,233 259.81 Loss of -5,506 on sale
2025-05-22SELL-176289.000291.540 291.286USD -51,266 259.56 Loss of -5,583 on sale
2025-05-20BUY88291.680292.990 292.859USD 25,772 259.00
2025-05-19BUY176291.860296.800 296.306USD 52,150 258.71
2025-05-16BUY264285.310289.750 289.306USD 76,377 258.47
2025-05-15BUY88283.400285.000 284.840USD 25,066 258.25
2025-05-12BUY352270.190270.200 270.199USD 95,110 257.98
2025-05-07BUY88276.550277.850 277.720USD 24,439 257.86
2025-04-25SELL-87251.560253.250 253.081USD -22,018 257.64 Profit of 397 on sale
2025-04-23BUY87241.970248.590 247.928USD 21,570 257.96
2025-04-22BUY87236.750238.630 238.442USD 20,744 258.18
2025-04-15SELL-261230.930242.150 241.028USD -62,908 259.60 Profit of 4,847 on sale
2025-04-10SELL-261226.280235.330 234.425USD -61,185 260.46 Profit of 6,795 on sale
2025-04-07SELL-87232.950241.830 240.942USD -20,962 261.42 Profit of 1,782 on sale
2025-04-02SELL-87266.830267.290 267.244USD -23,250 261.67 Loss of -485 on sale
2025-04-01BUY87255.760273.610 271.825USD 23,649 261.74
2025-03-31SELL-174270.020271.850 271.667USD -47,270 261.64 Loss of -1,745 on sale
2025-03-28SELL-87268.460271.300 271.016USD -23,578 261.55 Loss of -823 on sale
2025-03-25SELL-88280.960292.620 291.454USD -25,648 261.07 Loss of -2,674 on sale
2025-03-21BUY174283.340289.440 288.830USD 50,256 260.37
2025-03-19BUY87253.440255.350 255.159USD 22,199 260.56
2025-03-18SELL-87244.300263.300 261.400USD -22,742 260.79 Loss of -53 on sale
2025-03-17BUY174253.110253.300 253.281USD 44,071 260.90
2025-03-13SELL-87241.750245.140 244.801USD -21,298 261.46 Profit of 1,450 on sale
2025-03-07BUY87244.520251.120 250.460USD 21,790 262.82
2025-03-05BUY261249.230249.820 249.761USD 65,188 263.04
2025-02-26BUY95243.860251.600 250.826USD 23,828 264.78
2025-02-25SELL-87245.200251.560 250.924USD -21,830 265.13 Profit of 1,235 on sale
2025-02-21SELL-87250.590253.700 253.389USD -22,045 265.68 Profit of 1,070 on sale
2025-02-12BUY88265.960268.200 267.976USD 23,582 267.03
2025-02-06BUY88278.250279.240 279.141USD 24,564 266.36
2025-01-31SELL-88271.310279.340 278.537USD -24,511 265.67 Loss of -1,133 on sale
2025-01-29SELL-88273.990279.700 279.129USD -24,563 265.15 Loss of -1,231 on sale
2025-01-28SELL-176279.190283.560 283.123USD -49,830 264.77 Loss of -3,231 on sale
2025-01-24BUY264278.760279.670 279.579USD 73,809 264.02
2025-01-23SELL-176275.540277.220 277.052USD -48,761 263.69 Loss of -2,352 on sale
2025-01-02SELL-88233.620239.990 239.353USD -21,063 264.60 Profit of 2,221 on sale
2024-12-09SELL-88255.890258.120 257.897USD -22,695 265.22 Profit of 645 on sale
2024-12-06BUY174256.260257.810 257.655USD 44,832 265.52
2024-11-25SELL-1,127250.980255.460 255.012USD -287,399 270.92 Profit of 17,931 on sale
2024-11-22BUY103244.890248.900 248.499USD 25,595 272.22
2024-11-20BUY103248.790249.100 249.069USD 25,654 274.94
2024-11-18BUY206232.270242.490 241.468USD 49,742 280.15
2024-11-12BUY408268.950270.770 270.588USD 110,400 280.89
2024-11-07BUY102272.220275.070 274.785USD 28,028 281.83
2024-11-04SELL-309269.950272.920 272.623USD -84,241 285.55 Profit of 3,994 on sale
2024-10-30BUY103281.490287.870 287.232USD 29,585 290.50
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ALNY

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19216,7273,259396,24354.7%
2025-09-18172,875397386,43244.7%
2025-09-17246,547167472,29252.2%
2025-09-1688,84660226,33639.3%
2025-09-15148,25813,572435,68934.0%
2025-09-12134,122300244,96854.8%
2025-09-11219,8687,820411,70253.4%
2025-09-10543,3267,595916,89859.3%
2025-09-09705,54033,7311,550,89945.5%
2025-09-08175,158440388,71545.1%
2025-09-05127,116335311,25240.8%
2025-09-04110,9302,555236,56846.9%
2025-09-03182,3868,982562,92132.4%
2025-09-02132,77014,416358,47637.0%
2025-08-2993,2162,181276,59433.7%
2025-08-2860,1821,254226,86526.5%
2025-08-27277,6671,084440,57763.0%
2025-08-26243,404919447,42154.4%
2025-08-25156,55115,662374,27641.8%
2025-08-22228,5961,309408,15256.0%
2025-08-21123,9962,862248,30049.9%
2025-08-20149,63813,723316,98347.2%
2025-08-19144,3201,143308,39946.8%
2025-08-18371,31834,264525,78670.6%
2025-08-15104,01813,245265,62039.2%
2025-08-14133,2724,443505,52826.4%
2025-08-13183,2711,3901,017,62318.0%
2025-08-12173,0454,046693,01825.0%
2025-08-11239,1997,600451,24853.0%
2025-08-08168,7553,199466,74436.2%
2025-08-07308,8104,452527,39958.6%
2025-08-06202,15112,590548,34936.9%
2025-08-05256,29513,237826,28331.0%
2025-08-04411,11436,303729,94956.3%
2025-08-01350,06060,108764,94345.8%
2025-07-31829,1916,0231,541,01553.8%
2025-07-30533,88514,703942,78856.6%
2025-07-29164,26855384,53742.7%
2025-07-28150,24069571,96526.3%
2025-07-2590,782429298,80130.4%
2025-07-24132,00111,546286,15546.1%
2025-07-23184,14963312,34059.0%
2025-07-22134,7617,553524,61225.7%
2025-07-21113,303101243,11946.6%
2025-07-1884,1179196,31742.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Copyright Market Footprint Ltd. Privacy Policy